The Academy of Managed Care Pharmacy on July 16 submitted comments to the Department of Health and Human Services on the agency’s blueprint to trim drug prices and out-of-pocket costs.
The Trump administration revealed the blueprint in May this year.
“Many of the suggestions have been offered in other ways throughout the past decade, and AMCP has advocated for several of the ideas, including initiatives to spur generic and biosimilar market competition, allowing plans more flexibility in managing Medicare Part D and shifting Part B drugs to Part D,” a press release from AMCP states.
According to AMCP, the blueprint failed to include provisions for HHS to negotiate the price of domestic drugs or drugs imported from Canada and abroad.
“Also absent are calls specifically assessing the quality of prescription medications in improving patient outcomes, an important issue to AMCP,” the release states.
To read AMCP’s full letter to HHS, click here.
For more information on HHS’ drug pricing blueprint, click here.